Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ471,5472-0,42
KB5865871,73
PKN53,4253,44-0,89
Msft0,64
Nokia3,4143,421,11
IBM0,12
Daimler AG56,5556,570,89
PFE1,92
27.11.2020 23:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 27.11.2020
Jazz Pharma (JAZZ.O, NASDAQ Cons)
Závěr k 27.11.2020 Změna (%) Změna (USD) Objem obchodů (ks)
143,28 1,02 1,45 173 352
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.11.2020
Popis společnosti
Obecné informace
Název společnostiJazz Pharmaceuticals PLC
TickerJAZZ
Kmenové akcie:Ordinary Shares
RICJAZZ.O
ISINIE00B4Q5ZN47
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.09.2020
Počet zaměstnanců k 31.12.2019 1 620
Akcie v oběhu k 27.10.2020 55 714 006
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
UliceFifth Fl
MěstoDUBLIN
PSČ4
ZeměIreland
Kontatní osobaDiane Schrick
Funkce kontaktní osobySenior Director, Investor Relations
Telefon35 316 347 800
Fax35316347850
Kontatní telefon16 504 962 800

Business Summary: Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial Summary: BRIEF: For the nine months ended 30 September 2020, JazzPharmaceuticals PLC revenues increased 7% to $1.7B. Netincome decreased 77% to $105.2M. Revenues reflect Xyremsegment increase of 8% to $1.3B, Sunosi segment increasefrom $987K to $19.6M, United States segment increase of 7%to $1.54B, Europe segment increase of 17% to $125.2M. Netincome was offset by Acquired in-process research anddevelop increase of 96% to $215.3M (expense), Selling.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 28.11.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerBruce Cozadd5601.01.2003
President, Chief Operating OfficerDaniel Swisher5703.01.201803.01.2018
Chief Financial Officer, Executive Vice PresidentRenee Gala4816.03.202016.03.2020
Executive Vice President, General Manager - North AmericaKimberly Sablich5001.06.202001.06.2020
Executive Vice President, Research and DevelopmentRobert Iannone53
Senior Vice President, General CounselNeena Patil45
Senior Vice President - Technical OperationsFinbar Larkin62
Senior Vice President, Europe and Rest of WorldSamantha Pearce5402.03.202002.03.2020
Vice President, Finance and Principal Accounting OfficerPatricia Carr49